In-vitro activity of nisin against clinical isolates of Clostridium difficile

Journal of Chemotherapy

Volumn 16, Issue 2, 2004, Pages 119-121

  Bartoloni, A ^a   Mantella, A ^a   Goldstein, B P ^b   Dei, R ^a   Benedetti, M ^a   Sbaragli, S ^a   Paradisi, F ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b AMBI Inc   (United States)

Author keywords

Clostridium difficile; Hospital acquired diarrhea; Nisin; Peptide antibiotics

Indexed keywords

METRONIDAZOLE; NISIN; POLYPEPTIDE ANTIBIOTIC AGENT; VANCOMYCIN;

ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; CLOSTRIDIUM DIFFICILE; CONCENTRATION RESPONSE; DIARRHEA; LACTOCOCCUS LACTIS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN;

EID: 2942579097     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2004.16.2.119     Document Type: Article

References (12)

1. Allen SD, Emery CL, Siders JA. Clostridium. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, eds. Manual of Clinical Microbiology. 7th ed. Washington, DC. 1999.
2. Fekety R. Pseudomembranous colitis. In: Bennett JC, Plum F, eds. Cecil Textbook of Medicine. 20th ed, WB Saunders Company, Philadelphia, PA. 1996: 1633-1635.
3. Wilcox MH, Spencer RC. Clostridium difficile infection: responses, relapses, and re-infections. J Hosp Infection 1992; 22: 85-92.
4. Hancock REW, Chapple DS. Peptide antibiotics. Antimicrob Agents Chemother 1999; 43: 1317-1323.
5. Breukink E, Wiedemann I, van Kraaij C, Kuipers OP, Sahl H, de Kruijff B. Use of the cell wall precursor lipid II by a pore-forming peptide antibiotic. Science 1999; 286: 2245-2247.
6. Sell TL, Schaberg DR, Fekety FR. Bacteriophage and bacteriocin typing scheme for Clostridium difficile. J Clin Microbiol 1983; 17: 1148-1152.
7. Dei R. Observations on phage-typing of Clostridium difficile: preliminary evaluation of a phage panel. Eur J Epidemiol 1989; 5:351-354.
8. National Committee for Clinical Laboratory Standards. Methods for Antimicrobial Susceptibility Testing for Anaerobic Bacteria. 4th ed. Approved Standard M11-A4. NCCLS, Villanova, PA. 1997.
9. Spencer RC. Clinical impact and associated costs of Clostridium difficile-associated disease. J Antimicrob Chemother 1998; 41 (Suppl C): 5-12.
10. Wilcox MH. Treatment of Clostridium difficile infection. J Antimicrob Chemother 1998; 41 (Suppl C): 41-46.
11. Barbut F, Decre D, Burghoffer B, et al. Antimicrobial susceptibilities and serogroups of clinical strains of Clostridium difficile isolated in France in 1991 and 1997. Antimicrob Agents Chemother 1999; 43 (11): 2607-2611.
12. Kerr KG, Copley RM, Wilcox MH. Activity of nisin against Clostridium difficile. Lancet 1997; 349: 1026-1027.